ARF Bio Yenilenebilir Enerji Uretim AS

As of June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS carries a market capitalization of 5.69B, placing it among publicly traded companies globally. Its enterprise value stands at 5.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS has 182.84M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.86, and the price-to-book ratio stands at 2.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 11.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.27B versus a market cap of 5.69B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS maintains a current ratio of 4.89, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.28, indicating elevated leverage, while an interest coverage ratio of -0.18 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 9.02M in revenue per employee across its workforce of 49.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS recorded 23.36M in income tax expense. The company reported a pretax loss of -97.31M and -120.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 16.72, while the 200-day moving average is 26.06.

Over the twelve months ended June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS generated 442.02M in revenue and converted that into -120.67M in net income, yielding earnings per share of -0.66. EBITDA reached -23.61M, while operating income came in at -55.07M.

As of June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS holds 715.65M in cash and equivalents against 302.70M in total debt, resulting in a net debt position of 175.04M. Total book value stands at 2.12B, with working capital of 1.01B providing operational flexibility.

ARF Bio Yenilenebilir Enerji Uretim AS produced -556.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.31M in capital expenditures, free cash flow totaled -568.17M - equivalent to -3.11 per share.

Over the twelve months ended June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS posted a gross margin of 9.24, reflecting its pricing power and cost economics. The operating margin of -12.46 and net profit margin of -27.30 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.17, meaning ARF Bio Yenilenebilir Enerji Uretim AS raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ARF Bio Yenilenebilir Enerji Uretim AS has an Altman Z-Score of 6.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.